News stories about Pulmatrix (NASDAQ:PULM) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulmatrix earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.6278282434615 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Pulmatrix (PULM) traded up $0.02 on Tuesday, reaching $1.64. 168,000 shares of the company’s stock traded hands, compared to its average volume of 1,916,595. The company has a current ratio of 1.99, a quick ratio of 1.99 and a debt-to-equity ratio of 0.11. Pulmatrix has a 1-year low of $0.50 and a 1-year high of $6.98.
Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.08. The company had revenue of $0.34 million for the quarter. analysts expect that Pulmatrix will post -1.05 EPS for the current year.
Separately, Dawson James restated a “buy” rating on shares of Pulmatrix in a research note on Wednesday, September 27th.
TRADEMARK VIOLATION NOTICE: “Pulmatrix (PULM) Earns Media Sentiment Rating of 0.18” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/14/pulmatrix-pulm-earns-media-sentiment-rating-of-0-18.html.
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.